RF vs SPRO
RF (RF) versus Spero Therapeutics Inc (SPRO) — a side-by-side from cached financials, not a winner call.
RF (RF) common stock.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
RF does not have a complete income-statement cache yet.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
RF currently screens at market cap $0. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
Not investment advice. Open the RF and SPRO stock pages for the full models.
Not investment advice.